掌腱膜部分切除术治疗掌腱膜挛缩症17例

掌腱膜挛缩症是以掌腱膜增生、收缩引起手指屈曲挛缩为特征的一种系统性进行性疾病，病因不清，治疗现多倾向于局限性切除即部分切除术为最常用。自1994年8月～2005年6月，我们采用掌腱膜部分切除术治疗掌腱膜挛缩症17例，疗效满意，报道如下。     

掌腱膜挛缩症的手术治疗

掌腱膜挛缩症是指掌筋膜及手指筋膜广泛的纤维变性 ,以皮下结节和纤维束带为特征 ;导致手指继发性屈曲挛缩畸形 ,并伴皮下脂肪变薄 ,皮肤与病变处粘连凹陷为特征的疾病[1] 。1993年以来 ,我院共收治 17例 ,均采用手术治疗 ,获得了满意的效果。一、资料与方法1.一般资料 :本组共 17例 18指 ,男 16例 ,女 1例 ;年龄43～ 65岁 ,平均 5 3岁。右手 12例 ,左手 5例。病变分型 :(1)轻度 :手指掌指关节、近侧指间关节、远侧指间关节屈曲挛缩度数的总和 <45° ;本组共 9指。 (2 )中度 :手指ＤＰ、ＰＩＰ、ＤＩＰ屈曲挛缩度数的总和为 45°～ 90° ;本…     

掌腱膜挛缩症的治疗进展

掌腱膜挛缩症（Dupuytren'sDisease）流行于北欧及其他欧美地区，是以掌腱膜增生、收缩引起手指屈曲挛缩为特征的一种病症。早在1833年GuillaumeDupuytren在巴黎就作过一个专题报告。170多年来对于该病的发病原因的探究一直是医学界关心的热门课题。近年来，杂志上有不少专题报告介绍利用分子生物学、细胞生物学遗传学技术进行掌腱膜挛缩症的基础研究，并取得了一定的进展。HandClinics在1999年还出一期专刊，特此综述供同道们参考。１掌筋膜综合体的解剖与病理１．１解剖学研究Rayan用手术显微镜和小型关节镜对10具尸体手的掌腱膜作详尽…     

掌腱膜挛缩症的手术治疗

1997年10月-2005年7月，我科对11例（17指）掌腱膜挛缩症的患者进行了手术治疗，效果满意。     

掌腱膜挛缩症的诊断与治疗

掌腱膜挛缩是一种进行性增殖组织纤维变性病,好发于老年人,主要以掌腱膜增厚,收缩,手指屈曲挛缩为特征的手部畸形,多伴有手掌皮下脂肪变薄,皮肤凹陷并与掌腱膜粘连。本病以欧美国家多见,国内发病率较低,但近年发病率呈上升趋势,可能与社会人口中老年人比例增加,生活条件改善等原因有关[1-3]。1资料与方法本组13例,年龄30～73岁,男女之比为10:3,病程1个月～2年,其中12人为体力劳动者,1人为非体力劳动者。患病手指:中指2指,环指10指,小指8指。双侧3例,单侧10例,其中左侧者4例,右侧者6例。根据黄硕麟分型标准:Ⅱ型1例,Ⅲ3例,Ⅳ9例。有明确家族…     

手术显微镜下切除掌腱膜治疗掌腱膜挛缩症的方法及体会

１８２３年法国Ｄｕｐｕｙｔｒｅｎ报告掌腱膜挛缩症是由于掌腱膜挛缩而引起的手部继发性畸形。我院自１９８０年以来，在手术显微镜下切除掌腱膜治疗掌腱膜挛缩症２１例，收到良好的效果。１临床资料本组男１８例，女３例，年龄１９～７４岁，平均５３岁。工人１７例，干...     

保守治疗掌腱膜挛缩症1例

1病例资料患者男,70岁,左手掌环指根部皮肤皱褶,左环指背伸活动受限3月余。专科体检:为右利手,左环指根部掌侧皮肤皱褶突出,轻压痛VAS 2分,无放射痛。掌指关节、指间关节背伸活动受限,环指MP的AROM范围为40°~75°,PROM范围为30°~85°,环指TAM=(75°+85°+55°)-(40°+25°+10°)=140°,TPM=(85°+95°+68°)-(30°+10°+5°)=203°;握力:左手(患)∶右手(健)=15 kg∶35 kg,拇指-环指对指捏力:左手(患)∶右手(健)=3 kg∶6 kg。     

69例掌腱膜挛缩症治疗的护理

我院于1979年1月～2001年1月收治69例掌腱膜挛缩症患者,现将其临床护理体会报道如下。1临床资料本组69例,男62例,女7例;年龄33～83岁,平均64.3岁;病程10天～10年。受累手指113指:其中示指1指,中指22指,环指54指,小指36指。受累关节:掌指关节75个,近侧指间关节22个。其他体征:伴有指节垫1例,跖筋膜紧张4例,阴茎背侧结节1例。家族史:1例曾祖父有类似病史。伴发的慢性疾病:呼吸系统26例,心血管系统12例,高血压11例,消化系统病9例,颈椎病5例,类风湿性关节炎3例,糖尿病3例。2结果本组手术治疗65例,其中掌腱膜部分切除46例,随访44例;掌腱膜全部切…     

国人掌腱膜挛缩症的诱因及显微外科治疗

１９７９年１月～１９９７年１２月,本院治疗掌腱膜挛缩症（Ｄｕｐｕｙｔｒｅｎｓｃｏｎｔｒａｃｔｕｒｅ,简称ＤＣ）４２例,全部汉族。男３６例,女６例,男女之比６１。年龄３３岁～７８岁,平均６２．６岁。５０岁前６例,５１岁～６０岁１０例,６１岁～７０岁１５...     

Non-Dupuytren's disease of the palmar fascia

The typical Dupuytren's disease patient is of Northern European descent with bilateral progressive multiple digital contractures and is genetically predisposed, with a family history. Palmar fascial proliferations sometimes present as a different entity without the typical Dupuytren's disease characteristics. We identified 39 patients (20 women and 19 men) over a 4-year period with "Non-Dupuytren's palmar fascial disease", with unilateral involvement, without family history or ectopic manifestations. Twenty-three patients presented with unrelated complaints and were discovered, incidentally, to have the condition. In 28 patients, prior ipsilateral hand surgery or trauma precipitated the condition. Other related factors were diabetes mellitus and cardiovascular disease. Ten patients had skin tethering and subcutaneous thickening akin to Dupuytren's nodules and 29 had palmar fascial thickening into ill-defined pretendinous cords. The diseased tissue was in the line of the ring finger in 30 patients. The time from insult to onset of contracture averaged 3.6 months and from onset to follow-up averaged 5.3 years. The condition was non-progressive, or partially regressive, in 33 patients. Seven patients had operations for unrelated conditions and underwent simultaneous fasciectomy without recurrence. Environmental factors, especially trauma, surgery and diabetes, are important in the pathogenesis of Non-Dupuytren's palmar fascial disease, but these patients do not appear to be genetically predisposed for Dupuytren's disease. Typical Dupuytren's disease and Non-Dupuytren's palmar fascial disease are two clinical entities that run different courses and do not share a similar prognosis. This should be taken into account in future epidemiological and outcome studies.     

Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia

BACKGROUND: Dupuytren's contracture is a fibroproliferative disorder that is associated with increased collagen deposition. Isoforms of transforming growth factor beta (TGF(beta)), normally TGF(beta1) and TGF(beta2), are involved in the progressive fibrosis of Dupuytren's disease. It has been suggested that downregulation of TGF(beta) may be useful in the treatment of the condition. Tamoxifen, a synthetic nonsteroidal antiestrogen, is known to modulate the production of TGF(beta). This study examined the role of tamoxifen in decreasing fibroblast function and downregulating TGF(beta2). METHODS: Primary cultures of fibroblasts were obtained from Dupuytren's affected fascia and carpal tunnel affected fascia as a control. Collagen lattices were prepared and populated with the fibroblasts. The fibroblast-populated collagen lattices (FPCL) were then measured for contraction every 24 h for 5 days. Supernatant was obtained from the culture medium following completion of the FPCL portion of the experiment and used for a TGF(beta2) immunoassay. RESULTS: Dupuytren's affected fibroblasts contracted the FPCLs significantly more than carpal tunnel control fibroblasts. Treating the fibroblasts with tamoxifen caused a decreased contraction rate in both Dupuytren's affected fibroblasts and carpal tunnel controls. There was increased TGF(beta2) expression in the Dupuytren's affected fascia group compared to the carpal tunnel control group. Tamoxifen decreased TGF(beta2) expression in Dupuytren's affected fascia group but not in the carpal tunnel control group. CONCLUSION: TGF(beta) appears to be the key cytokine in the fibrogenic nature of Dupuytren's disease. Tamoxifen treatment has been demonstrated to decrease the function of fibroblasts derived from Dupuytren's affected fascia and downregulated TGF(beta2) production in these same fibroblasts. These data suggest a method to manipulate and control Dupuytren's contracture in the clinical setting.     

掌腱膜桡侧挛缩的临床特点与治疗

目的探讨掌腱膜桡侧挛缩的病变特点和临床疗效。方法对8例因掌腱膜桡侧挛缩行手术治疗的病例进行回顾性研究。8例的病变均位于虎口和大鱼际区域，表现为皮肤纠集、结节和条索，很少影响拇指的活动范围。均手术切除局部的掌腱膜条索。7例患者获得随访，平均随访25．1个月；1例失访。结果掌腱膜桡侧挛缩多与尺侧挛缩并发，手术治疗总体疗效较好，仅有1例复发。术后病理证实切除的组织为挛缩的掌腱膜。结论掌腱膜桡侧挛缩的发病部位集中于第一掌指关节的掌侧、大鱼际尺侧、虎口部位和大鱼际桡侧，未见累及指问关节，手术治疗可取得良好效果。     

Z成形术治疗重度臀肌筋膜挛缩症及其所致腰臀部畸形

目的探索重度臀肌筋膜挛缩症及其所致臀腰部畸形的最佳治疗方法。方法对25例重度臀肌筋膜挛缩症及其所致臀腰部畸形患者,依Z成形术原则进行挛缩带和挛缩瘢痕的松解后,将局部皮肤进行重新分配和塑形加以治疗。结果25例双侧髋关节功能完全恢复,步态正常,腰臀部形态基本平整,无坐骨神经损伤。术后随访6个月至3年,平均1．6年,无畸形复发。结论Z成形术既解除了挛缩带对关节功能的牵制,又可对局部皮肤进行重新分配,矫正挛缩造成的凹陷畸形,术后功能和外形效果均佳,是治疗重度臀肌筋膜症及其所致臀腰部畸形的良好方法。     

掌腱膜挛缩症合并腕管综合征的诊断和治疗

目的 探讨掌腱膜挛缩症与腕管综合征的相关性及一次完成两种手术的治疗效果.方法 2003年3月至2011年8月,对8例掌腱膜挛缩症合并腕管综合征的患者,其中右手5例、左手3例,设计手掌部“M”形切口,或同时加手指的“Y”形切口,同时切除部分掌腱膜,行屈肌支持带切开、正中神经松解术.结果 术后全部伤口均Ⅰ期愈合,无皮瓣边缘坏死及血肿形成,术后拇、示、中指麻木逐渐减轻,术后3个月手指麻木全部消失.术后随访时间为6个月至2年,掌腱膜挛缩无复发.结论 掌腱膜挛缩症与腕管综合征两种疾病的诱发因素较多地发生在同一个体时,两种疾病同时并发的几率明显增加,可通过一次手术完成.     

臀大肌止点上移松解术治疗重症臀肌挛缩症的远期疗效观察

[目的]探讨臀大肌止点上移松解术治疗重症臀肌挛缩症的远期疗效.[方法]160例重症臀肌李缩症患者分为两组,分别接受传统臀肌松解术及臀大肌止点上移松解术,平均随访66.3个月,比较其外展挛缩角度改善,并通过自制评分系统对疗效进行评价.[结果]134例随访患者中接受臀大肌止点上移松解术其外展挛缩角度改善及疗效评分均优于接受传统臀肌松解术患者.[结论]臀大肌止点上移松解治疗重症臀肌挛缩症远期疗效满意,优于传统臀肌松解术.     

Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives

The so-called fibrogenic cytokines, able to induce the growth of fibroblasts and their differentiation into myofibroblasts and to stimulate their production of extracellular matrix, are involved in the genesis of Dupuytren's contracture. Although many studies have been made of biomolecular aspects of palmar fibromatosis, practical applications from them are still far from imminent because of the real difficulty of blocking their action in vivo, even in a chronic, progressive lesion such as Dupuytren's disease. Consequently, surgical excision of the palmar fascia still remains the treatment of choice.     

Bloodflow in the Finger in Dupuytren's contracture

Summary 1. There is a high incidence of latent vasospastic changes in the hands of patients with DC regardless of the state of the disease. 2. The high incidence of vasospasm and ulnar nerve lesions in DC suggest, that in some ways these are related to the pathogenesis. 3. Comparing patients with a normal finger plethysmogram with those with a vasospastic vessel-reaction, there is no correlation concerning the ulnar nerve lesions in DC. Therefore we assume that these are independent constitutional factors. — 4. The disturbance in blood flow in the hand in DC is usually asymptomatic and is probably a different phenomenon from that seen in Raynaud's Syndrome.Partly read at the International Hand Surgery Congress, Melbourne, Australia, November 14, 1979     

关节镜微创治疗臀肌挛缩症

<正>2010年8月~2013年12月,我科在关节镜下治疗23例臀肌挛缩患者,疗效满意,现报道如下。1材料与方法1.1病例资料本组23例(35髋),男15例(22髋),女8例(13髋),年龄16~35岁;病程9~25年。参照贺西京的分级方法[1]分3级:Ⅰ级5例,Ⅱ级17例,Ⅲ级1例。左髋5例,右髋8例,     

Immunohistochemical evidence of nerve growth factor in Dupuytren's diseased palmar fascia

PURPOSE: Histologically, the pathognomic feature of Dupuytren's contracture (DC) is the myofibroblast. Its occurrence in this disease has been associated with local production of transforming growth factor (TGF)-B. However, nerve growth factor (NGF) is a recognized growth factor involved in wound healing and has been shown to induce the myofibroblast phenotype in cultured fibroblasts. We hypothesized that NGF would be abundant in this disease entity. METHODS: Immunohistochemistry was used to examine for the presence of NGF in 25 surgical specimens from patients with DC and in surgical specimens from 5 other, unrelated procedures. Patient demographics showed that nearly all patients were men, with a mean age of 61 years (range 36-77). Serial sections were probed with antibodies, stained, and then digitally photomicrographed. Disease staging was also performed. Image analysis was then used to measure the percentage of area stained. In addition, representative sections were probed for TrkA, the high-affinity receptor for NGF, and alpha-smooth muscle actin, a cytoskeletal marker of the myofibroblast phenotype. These alternate steps were used to infer functional dependence and the association of NGF with myofibroblast populations. RESULTS: Histologically, all patients had either stage II or III disease. Biopsy results showed an abundance of NGF--over double that of controls. The highest levels of NGF occurred in hypercellular stage II disease. In addition, we confirmed that NGF is linked to the expression of both TrkA receptors and alpha-smooth muscle actin. CONCLUSIONS: Tissue levels of NGF are elevated in Dupuytren's disease. This tissue is competent to respond to NGF and manifests an abundance of myofibroblasts in areas of NGF expression. Nerve growth factor is most apparent in the proliferative (hyperplastic) stage of the disease. These data infer that NGF is linked to the pathologic process.